Enoxaparin is an anticoagulant (blood thinner) medicine. It is used to treat and prevent deep vein thrombosis and pulmonary embolism, including during pregnancy and after certain surgeries. It is also used in patients with acute coronary syndrome (ACS) and heart attacks. Enoxaparin is also used to assist with hemodialysis. It is administered by injection directly under the skin or into a vein.



The mechanism of action of enoxaparin is antithrombin dependent. It acts primarily by accelerating the neutralization of certain activated clotting factors by antithrombin. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa, providing anticoagulation.


The bioavailability of enoxaparin after subcutaneous injection is nearly 100%. The drug is 80% bound to plasma proteins. Enoxaparin is metabolized primarily in the liver by desulfation and/or depolymerization to lower molecular weight metabolites with greatly reduced biological potency. Total renal excretion of active and non-active fragments accounts for approximately 40% of the dose. The plasma half-life is approximately 4.5 hours.

Drug Interactions

Enoxaparin should not be used together with other anticoagulants.


Side effects

  • bleeding, especially of the skin and mucous membranes, bleeding anaemia, thrombocytopenia, thrombocytosis
  • allergic reactions like urticaria, pruritus, erythema
  • Headache
  • Transaminase increase
  • injection site reactions
  • accumulation in renal insufficiency

Chemical & physical properties

ATC Code B01AB05
Physical State solid
Melting Point (°C) 140
CAS Number 679809-58-6
PUB Number 772
Drugbank ID DB01225

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc

Markus Falkenstätter, BSc

Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.

The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.


Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.